Program
garadacimab
Also written as “CSL312”, “Garadacimab” and “Factor XIIa antagonist monoclonal antibody”.
Its studies are mostly in Angioedemas, Hereditary · Idiopathic Pulmonary Fibrosis, led by CSL.
Furthest: phase 4, since Feb 3, 20259 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSL | 90 open or running | phase 4since Feb 3, 2025 | Oct 17, 2018 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 17, 2018First study: phase 2 study in Angioedemas, HereditaryFirst studyNCT03712228 · 44 enrolled · United States, Australia, Canada and more
- Feb 21, 2020Phase 2 study in PICC-associated ThrombosisNCT04281524
- Oct 2, 2020Phase 1 study in Healthy VolunteersNCT04580654 · 38 enrolled · United States
- Dec 1, 2020Phase 3 study in Angioedemas, HereditaryNCT04656418 · 64 enrolled · United States, Canada, Germany and more
- Feb 1, 2021Phase 3 study in Angioedemas, HereditaryNCT04739059 · 171 enrolled · United States, Australia, Canada and more
- Nov 12, 2021Phase 2 study in Idiopathic Pulmonary FibrosisNCT05130970 · 81 enrolled · United States, Australia, Austria and more
- Mar 23, 2022Phase 1 study in Healthy ParticipantsNCT05306275 · 132 enrolled · United States
- Apr 4, 2023Phase 3 study in Angioedemas, HereditaryNCT05819775 · 22 enrolled · United States, Australia, Canada and more
- Feb 3, 2025Phase 4 study in Angioedemas, HereditaryNCT06806657 · 18 enrolled · United States, Canada, Germany
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06806657Angioedemas, Hereditary · United States, Canada, Germany | 4 | Completed | Jun 29, 2026 | 18 |
| NCT05819775Angioedemas, Hereditary · United States, Australia, Canada and more | 3 | Completed | Nov 19, 2025 | 22 |
| NCT05306275Healthy Participants · United States | 1 | Completed | Sep 27, 2022 | 132 |
| NCT05130970Idiopathic Pulmonary Fibrosis · United States, Australia, Austria and more | 2 | Completed | Jan 2, 2024 | 81 |
| NCT04739059Angioedemas, Hereditary · United States, Australia, Canada and more | 3 | Completed | Nov 21, 2025 | 171 |
| NCT04656418Angioedemas, Hereditary · United States, Canada, Germany and more | 3 | Completed | Jun 7, 2022 | 64 |
| NCT04580654Healthy Volunteers · United States | 1 | Completed | May 7, 2021 | 38 |
| NCT04281524PICC-associated Thrombosis | 2 | Withdrawn | Aug 2021 | 0 |
| NCT03712228Angioedemas, Hereditary · United States, Australia, Canada and more | 2 | Completed | Oct 15, 2021 | 44 |
How it is read
Names in the registry
- “CSL312”, 6 entries
- “Garadacimab”, 2 entries
- “Factor XIIa antagonist monoclonal antibody”, 1 entry
Conditions, from the studies’ own filings
- Angioedemas, Hereditary, 5 studies
- Idiopathic Pulmonary Fibrosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.